Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

Beam Therapeutics Inc. (BEAM)

39.79   1.08 (2.79%) 07-02 20:28
Open: 39 Pre. Close: 38.71
High: 40.13 Low: 38.29
Volume: 1,106,012 Market Cap: 2,796(M)
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia; and BEAM-301, a liver-targeted development candidate for the treatment of patients with Glycogen Storage Disease Type Ia. It also develops therapies for alpha-1 antitrypsin deficiency; ocular diseases; and other liver, muscle, and central nervous system disorders. The company has an alliance with Boston Children's Hospital; a research and clinical trial collaboration agreement with Magenta Therapeutics, Inc.; license agreement with Sana Biotechnology, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration agreement with Pfizer Inc. and Apellis Pharmaceuticals, Inc.; and collaboration and license agreement with Verve Therapeutics, Inc. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 40.17 - 40.36 40.36 - 40.53
Low: 37.84 - 38.05 38.05 - 38.24
Close: 39.45 - 39.8 39.8 - 40.1

Technical analysis

as of: 2022-07-01 4:20:22 PM
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 51.46     One year: 60.1
Support: Support1: 34.15    Support2: 28.04
Resistance: Resistance1: 44.06    Resistance2: 51.46
Pivot: 37.33
Moving Average: MA(5): 40.48     MA(20): 37.27
MA(100): 48.3     MA(250): 71.84
MACD: MACD(12,26): 1     Signal(9): 0.5
Stochastic oscillator: %K(14,3): 72.4     %D(3): 76.2
RSI: RSI(14): 54.3
52-week: High: 116.91  Low: 27.77
Average Vol(K): 3-Month: 1,404 (K)  10-Days: 1,628 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ BEAM ] has closed below upper band by 35.5%. Bollinger Bands are 12.1% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

Sat, 02 Jul 2022
Apollo Proton Cancer Centre introduces proton beam therapy -

Sat, 02 Jul 2022
Electron Beam Irradiation Service Market 2022-2028: STERIS AST,CGN Nuclear Technology Development,BSG,NHV,E-BEAM Services,Guangzhou Huada Biotechnology,Sterigenics,Lanfu High-energy,Beijing Hongyisifang,Shaanxi Fangyuan Industrial Grou - Designer Women

Sat, 02 Jul 2022
Chilled Beam Systems Market Insights 2022 And Analysis By Top Keyplayers – Caverion, TROX GmbH, Halton Group, Lindab – Designer Women - Designer Women

Sat, 02 Jul 2022
Mary Ruth (Happeny) Beam | Obituaries | - Sentinel-Tribune

Fri, 01 Jul 2022
Yorktown's Riverwalk Landing parking structure fully open again after support beam damage - Daily Press

Fri, 01 Jul 2022
Elon Musk's Starlink Can Now Beam Wifi to Cars, Boats, and Planes - Gizmodo

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 68 (M)
% Held by Insiders 5.721e+007 (%)
% Held by Institutions 1.9 (%)
Shares Short 8,820 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS -2.3006e+008
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin (%) 0
Operating Margin (%) -458.2
Return on Assets (ttm) -15.5
Return on Equity (ttm) -69.2
Qtrly Rev. Growth 851
Gross Profit (p.s.) 40.98
Sales Per Share 4.24918e+007
EBITDA (p.s.) 4.24918e+007
Qtrly Earnings Growth -6.6
Operating Cash Flow 0 (M)
Levered Free Cash Flow -66 (M)

Stock Valuations

PE Ratio -0.01
PEG Ratio -1.8
Price to Book value 0
Price to Sales 0
Price to Cash Flow 3.77

Stock Dividends

Dividend 0
Forward Dividend 1.081e+007
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.